Payment overview · 2025
General Payments
$481.14
29 reported records · 8 companies
Healthcare provider profile · identity verified
Joseph Edward Mickelson, MD
Allopathic & Osteopathic Physicians|Family Medicine · CASPER, WY · NPI 1467448043
Verified facts
What the public records show
CMS Open Payments records show Joseph Edward Mickelson, MD received $481.14 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $163.65 | 34.0% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.33 | 15.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.72 | 12.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.86 | 12.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.25 | 11.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.27 | 4.8% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $21.73 | 4.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.33 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $465.15 | 28 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $76.33 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $72.58 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $72.27 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.86 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $57.86 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.25 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.74 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.00 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 90 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
81 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
87 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1003 | 215 |
| Atorvastatin Calcium | Atorvastatin Calcium | 787 | 182 |
| Amlodipine Besylate | Amlodipine Besylate | 570 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 556 | 114 |
| Furosemide | Furosemide | 507 | 96 |
| Losartan Potassium | Losartan Potassium | 440 | 117 |
| Lisinopril | Lisinopril | 431 | 110 |
| Simvastatin | Simvastatin | 404 | 100 |
| Allopurinol | Allopurinol | 387 | 94 |
| Potassium Chloride | Potassium Chloride | 383 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 365 | 77 |
| Omeprazole | Omeprazole | 349 | 90 |
| Gabapentin | Gabapentin | 335 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 303 | 68 |
| Tramadol Hcl | Tramadol Hcl | 296 | 61 |
| Metformin Hcl | Metformin Hcl | 282 | 73 |
| Famotidine | Famotidine | 278 | 58 |
| Meloxicam | Meloxicam | 229 | 57 |
| Trazodone Hcl | Trazodone Hcl | 223 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 202 | 38 |
| Sertraline Hcl | Sertraline Hcl | 185 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 184 | 41 |
| Buspirone Hcl | Buspirone Hcl | 172 | 30 |
| Eliquis | Apixaban | 163 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 42 |
| Montelukast Sodium | Montelukast Sodium | 150 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 140 | 24 |
| Alendronate Sodium | Alendronate Sodium | 134 | 33 |
| Metformin Hcl Er | Metformin Hcl | 134 | 27 |
| Glimepiride | Glimepiride | 127 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 29 |
| Celecoxib | Celecoxib | 120 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 47 |
| Spironolactone | Spironolactone | 118 | 17 |
| Finasteride | Finasteride | 117 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 105 | 23 |
| Liothyronine Sodium | Liothyronine Sodium | 105 | 25 |
| Mirtazapine | Mirtazapine | 105 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 27 |
| Donepezil Hcl | Donepezil Hcl | 95 | 15 |
| Terazosin Hcl | Terazosin Hcl | 94 | 18 |
| Prednisone | Prednisone | 91 | 48 |
| Mounjaro | Tirzepatide | 90 | 12 |
| Alprazolam | Alprazolam | 89 | 15 |
| Ezetimibe | Ezetimibe | 89 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 14 |
| Pregabalin | Pregabalin | 82 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 13 |
| Synthroid | Levothyroxine Sodium | 81 | 23 |
| Estradiol | Estradiol | 73 | 20 |
| Warfarin Sodium | Warfarin Sodium | 73 | 13 |
| Carvedilol | Carvedilol | 70 | 16 |
| Jardiance | Empagliflozin | 70 | 17 |
| Ozempic | Semaglutide | 70 | 13 |
| Bupropion Xl | Bupropion Hcl | 68 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 68 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 18 |
| Myrbetriq | Mirabegron | 65 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 51 |
| Sucralfate | Sucralfate | 59 | 11 |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 16 |
| Olanzapine | Olanzapine | 56 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | 14 |
| Gemfibrozil | Gemfibrozil | 52 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 50 | suppressed |
| Diazepam | Diazepam | 48 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | 13 |
| Lorazepam | Lorazepam | 47 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 37 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 38 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 43 | suppressed |
| Nystatin | Nystatin | 43 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 12 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Irbesartan | Irbesartan | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 13 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Cephalexin | Cephalexin | 33 | 20 |
| Propranolol Hcl | Propranolol Hcl | 33 | 11 |
| Methylprednisolone | Methylprednisolone | 32 | 27 |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Dutasteride | Dutasteride | 29 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Etodolac | Etodolac | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Colchicine | Colchicine | 24 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 15 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 13 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Mirabegron Er | Mirabegron | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $481.14 · 29 records | ABBVIE INC. | BREZTRI, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error